Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J SMALL

Showing results (741-750 of 1,203) with videos related to

Pageof 121
Sort By:
Cancer|April 6, 2021
Prostate-specific antigen nadir and testosterone level at prostate-specific antigen failure following radiation and androgen suppression therapy for unfavorable-risk prostate cancer and the risk of all-cause and prostate cancer-specific mortalityDanielle S Bitterman, Ming-Hui Chen, Jing Wu, et al.
The Journal of Urology|March 29, 2021
Baseline Testosterone Levels in Men with Clinically Localized High-Risk Prostate Cancer Treated with Radical Prostatectomy with or without Neoadjuvant Chemohormonal Therapy (Alliance)James A Eastham, Glenn Heller, David W Hillman, et al.
Cancer|October 27, 2017
Sleep disturbance in men receiving androgen deprivation therapy for prostate cancer: The role of hot flashes and nocturiaBrian D Gonzalez, Brent J Small, Mallory G Cases, et al.
Contemporary Clinical Trials|October 6, 2015
Knowledge and attitudes regarding clinical trials and willingness to participate among prostate cancer patientsCelia P Kaplan, Anna Maria Nápoles, Steven Narine, et al.
Cancer|December 22, 2017
Low testosterone at first prostate-specific antigen failure and assessment of risk of death in men with unfavorable-risk prostate cancer treated on prospective clinical trialsKatelyn M Atkins, Ming-Hui Chen, Jing Wu, et al.
Cancer|September 24, 2010
A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006Joel Picus, Susan Halabi, W Kevin Kelly, et al.
Urologic Oncology|October 2, 2010
Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II studyTerence W Friedlander, Vivian K Weinberg, Eric J Small, et al.
Journal of Clinical Psychopharmacology|July 31, 2001
A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar maniaK Meehan, F Zhang, S David, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2001
Independent association of angiogenesis index with outcome in prostate cancerR Mehta, A Kyshtoobayeva, T Kurosaki, et al.
The Cancer Journal From Scientific American|June 5, 1998
The treatment of metastatic renal cell carcinoma patients with recombinant human gamma interferonE J Small, G R Weiss, U K Malik, et al.
Pageof 121

Showing results (741-750 of 1,203) with videos related to

Sort By:
Pageof 121
Cancer|April 6, 2021
Prostate-specific antigen nadir and testosterone level at prostate-specific antigen failure following radiation and androgen suppression therapy for unfavorable-risk prostate cancer and the risk of all-cause and prostate cancer-specific mortalityDanielle S Bitterman, Ming-Hui Chen, Jing Wu, et al.
The Journal of Urology|March 29, 2021
Baseline Testosterone Levels in Men with Clinically Localized High-Risk Prostate Cancer Treated with Radical Prostatectomy with or without Neoadjuvant Chemohormonal Therapy (Alliance)James A Eastham, Glenn Heller, David W Hillman, et al.
Cancer|October 27, 2017
Sleep disturbance in men receiving androgen deprivation therapy for prostate cancer: The role of hot flashes and nocturiaBrian D Gonzalez, Brent J Small, Mallory G Cases, et al.
Contemporary Clinical Trials|October 6, 2015
Knowledge and attitudes regarding clinical trials and willingness to participate among prostate cancer patientsCelia P Kaplan, Anna Maria Nápoles, Steven Narine, et al.
Cancer|December 22, 2017
Low testosterone at first prostate-specific antigen failure and assessment of risk of death in men with unfavorable-risk prostate cancer treated on prospective clinical trialsKatelyn M Atkins, Ming-Hui Chen, Jing Wu, et al.
Cancer|September 24, 2010
A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006Joel Picus, Susan Halabi, W Kevin Kelly, et al.
Urologic Oncology|October 2, 2010
Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II studyTerence W Friedlander, Vivian K Weinberg, Eric J Small, et al.
Journal of Clinical Psychopharmacology|July 31, 2001
A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar maniaK Meehan, F Zhang, S David, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2001
Independent association of angiogenesis index with outcome in prostate cancerR Mehta, A Kyshtoobayeva, T Kurosaki, et al.
The Cancer Journal From Scientific American|June 5, 1998
The treatment of metastatic renal cell carcinoma patients with recombinant human gamma interferonE J Small, G R Weiss, U K Malik, et al.
Pageof 121